Teva Pharmaceuticals is facing a difficult road ahead, thanks to 3,500 cases of litigation surrounding its role in the US opioid epidemic. But the manufacturer got a victory last week when a US appeals court upheld a 2020 finding that ruled in favor of the company in a lawsuit accusing the giant of patent violations.
Teva and Novartis’ Sandoz recently launched generic versions of Narcan on the same day, but it likely wasn’t a coincidence. Both first-to-market generics for Narcan, an opioid overdose rescue nasal spray, are FDA approved, but only Sandoz’ version is authorized by Narcan’s brand marketer Emergent BioSolutions.
Narcan Nasal Spray (naloxone hydrochloride) : Adapt Pharma vs. Perrigo UK FINCO Limited
Perrigo Confirms Patent Challenge For Generic Version Of Narcan®
US pharma group Emergent BioSolutions has completed the acquisition of Dublin-headquartered Adapt Pharma for the $635 million (€549 million).
Dublin-based Adapt Pharma recorded pre-tax profits of $19m (€16.46m) last year after revenues more than tripled.